Journal
MOLECULAR ONCOLOGY
Volume 6, Issue 6, Pages 657-682Publisher
WILEY
DOI: 10.1016/j.molonc.2012.09.004
Keywords
Epigenetics; Epi-drugs; Clinical trials; Cancer
Categories
Funding
- EU [282510]
- ATLAS [221952]
- Epigenomics Flagship Project EPIGEN (MIUR-CNR)
- Italian Association for Cancer Research (AIRC) [11812]
- Italian Ministry of University and Research [PRIN_2009PX2T2E_004, PON002782, PON0101227]
Ask authors/readers for more resources
Epigenetic inactivation of pivotal genes involved in correct cell growth is a hallmark of human pathologies, in particular cancer. These epigenetic mechanisms, including crosstalk between DNA methylation, histone modifications and non-coding RNAs, affect gene expression and are associated with disease progression. In contrast to genetic mutations, epigenetic changes are potentially reversible. Re-expression of genes epigenetically inactivated can result in the suppression of disease state or sensitization to specific therapies. Small molecules that reverse epigenetic inactivation, so-called epi-drugs, are now undergoing clinical trials. Accordingly, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for cancer treatment have approved some of these drugs. Here, we focus on the biological features of epigenetic molecules, analyzing the mechanism(s) of action and their current use in clinical practice. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available